EP3628049
Samrunaprótín af TGF-beta viðtaka af gerð II og notkun á þeim
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.5.2018EP published:
10.5.2023EP application number:
18794202.4
EP translation filed:
12.6.2023Grant published:
15.7.2023EPO information:
European Patent Register
Max expiry date:
2.5.2038Expiry date:
2.5.2026Next due date:
31.5.2026
Title in English:
TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND USES THEREOFLanguage of the patent:
English
Timeline
Today
3.5.2018EP application
10.5.2023EP Publication
12.6.2023Translation submitted
15.7.2023Registration published
2.5.2026Expires
Owner
Name:
Acceleron Pharma Inc.Address:
128 Sidney Street, Cambridge, MA 02139, US
Inventor
Name:
KUMAR, RavindraAddress:
Acton, MA 01720, US
Name:
SAKO, Dianne S.Address:
Medford, MA 02155, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762501229 PDate:
4.5.2017Country:
US
Number:
201762510422 PDate:
24.5.2017Country:
US
Number:
201762578674 PDate:
30.10.2017Country:
US
Classification
Categories:
C07K 14/71, C07K 16/46, A61K 38/17, A61P 9/12, A61P 9/10, A61P 13/12, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 12.4.2024
Expires: 2.5.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 6.5.2025
Expires: 2.5.2026
Payer: Árnason Faktor ehf.